258 related articles for article (PubMed ID: 25289773)
1. Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin.
De Jonghe S; Proctor J; Vinken P; Feyen B; Wynant I; Marien D; Geys H; Mamidi RN; Johnson MD
Chem Biol Interact; 2014 Dec; 224():1-12. PubMed ID: 25289773
[TBL] [Abstract][Full Text] [Related]
2. Renal tubular and adrenal medullary tumors in the 2-year rat study with canagliflozin confirmed to be secondary to carbohydrate (glucose) malabsorption in the 15-month mechanistic rat study.
De Jonghe S; Johnson MD; Mamidi RNVS; Vinken P; Feyen B; Lammens G; Proctor J
Chem Biol Interact; 2017 Nov; 277():85-90. PubMed ID: 28916336
[TBL] [Abstract][Full Text] [Related]
3. Carbohydrate malabsorption mechanism for tumor formation in rats treated with the SGLT2 inhibitor canagliflozin.
Mamidi RN; Proctor J; De Jonghe S; Feyen B; Moesen E; Vinken P; Ma JY; Bryant S; Snook S; Louden C; Lammens G; Ways K; Kelley MF; Johnson MD
Chem Biol Interact; 2014 Sep; 221():109-18. PubMed ID: 25130857
[TBL] [Abstract][Full Text] [Related]
4. Chronic toxic and carcinogenic effects of oral cadmium in the Noble (NBL/Cr) rat: induction of neoplastic and proliferative lesions of the adrenal, kidney, prostate, and testes.
Waalkes MP; Anver MR; Diwan BA
J Toxicol Environ Health A; 1999 Oct; 58(4):199-214. PubMed ID: 10591488
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D3-induced proliferative lesions in the rat adrenal medulla.
Tischler AS; Powers JF; Pignatello M; Tsokas P; Downing JC; McClain RM
Toxicol Sci; 1999 Sep; 51(1):9-18. PubMed ID: 10496673
[TBL] [Abstract][Full Text] [Related]
6. Development of alpha2u-globulin nephropathy and adrenal medullary pheochromocytomas in male rats following exposure to Stoddard solvent IIC.
Doi A; Peckham J; Chou B; Dill J; Renne R; Grumbein S; Chhabra R
Inhal Toxicol; 2004 May; 16(5):247-57. PubMed ID: 15371178
[TBL] [Abstract][Full Text] [Related]
7. Successful integration of nonclinical and clinical findings in interpreting the clinical relevance of rodent neoplasia with a new chemical entity.
Ways K; Johnson MD; Mamidi RN; Proctor J; De Jonghe S; Louden C
Toxicol Pathol; 2015 Jan; 43(1):48-56. PubMed ID: 25398756
[TBL] [Abstract][Full Text] [Related]
8. NTP Toxicology and Carcinogenesis Studies of 1,4-Dichlorobenzene (CAS No. 106-46-7) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1987 Jan; 319():1-198. PubMed ID: 12748734
[TBL] [Abstract][Full Text] [Related]
9. Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2.
Ohgaki R; Wei L; Yamada K; Hara T; Kuriyama C; Okuda S; Ueta K; Shiotani M; Nagamori S; Kanai Y
J Pharmacol Exp Ther; 2016 Jul; 358(1):94-102. PubMed ID: 27189972
[TBL] [Abstract][Full Text] [Related]
10. Physiologically based pharmacokinetic-pharmacodynamic modeling to predict concentrations and actions of sodium-dependent glucose transporter 2 inhibitor canagliflozin in human intestines and renal tubules.
Mori K; Saito R; Nakamaru Y; Shimizu M; Yamazaki H
Biopharm Drug Dispos; 2016 Nov; 37(8):491-506. PubMed ID: 27604638
[TBL] [Abstract][Full Text] [Related]
11. Invokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in Alzheimer's disease- diabetes type 2 linkage via an enzoinformatics study.
Rizvi SM; Shakil S; Biswas D; Shakil S; Shaikh S; Bagga P; Kamal MA
CNS Neurol Disord Drug Targets; 2014 Apr; 13(3):447-51. PubMed ID: 24059302
[TBL] [Abstract][Full Text] [Related]
12. NTP Toxicology and Carcinogenesis Studies of Nitrofurantoin (CAS No. 67-20-9) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1989 Sep; 341():1-218. PubMed ID: 12724784
[TBL] [Abstract][Full Text] [Related]
13. SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1.
Novikov A; Fu Y; Huang W; Freeman B; Patel R; van Ginkel C; Koepsell H; Busslinger M; Onishi A; Nespoux J; Vallon V
Am J Physiol Renal Physiol; 2019 Jan; 316(1):F173-F185. PubMed ID: 30427222
[TBL] [Abstract][Full Text] [Related]
14. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study.
Polidori D; Sha S; Mudaliar S; Ciaraldi TP; Ghosh A; Vaccaro N; Farrell K; Rothenberg P; Henry RR
Diabetes Care; 2013 Aug; 36(8):2154-61. PubMed ID: 23412078
[TBL] [Abstract][Full Text] [Related]
15. NTP Toxicology and Carcinogenesis Studies of Phenolphthalein (CAS No. 77-09-8) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Nov; 465():1-354. PubMed ID: 12579199
[TBL] [Abstract][Full Text] [Related]
16. NTP Toxicology and Carcinogenesis Studies of Pentachloroanisole (CAS No. 1825-21-4) in F344 Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Apr; 414():1-284. PubMed ID: 12616284
[TBL] [Abstract][Full Text] [Related]
17. Pathogenesis of Renal Injury and Gene Expression Changes in the Male CD-1 Mouse Associated with Exposure to Empagliflozin.
Knight B; Yuan J; Koegler S; Pande P; Hall J; Hill JD; Hart SE; Phillips JA; Ku WW
Toxicol Pathol; 2018 Aug; 46(6):671-682. PubMed ID: 29945496
[TBL] [Abstract][Full Text] [Related]
18. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
[TBL] [Abstract][Full Text] [Related]
19. Toxicology and Carcinogenesis Studies of C.I. Pigment Red 3 (CAS No. 2425-85-6) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1992 Mar; 407():1-289. PubMed ID: 12621523
[TBL] [Abstract][Full Text] [Related]
20. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level.
Katsuno K; Fujimori Y; Takemura Y; Hiratochi M; Itoh F; Komatsu Y; Fujikura H; Isaji M
J Pharmacol Exp Ther; 2007 Jan; 320(1):323-30. PubMed ID: 17050778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
